Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy
Tweet
Share
E-mailGet Alerts CNAT Hot Sheet
Price: $0.56 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Roth Capital assumed/initiated coverage on Conatus Pharmaceuticals (NASDAQ: CNAT) with a Buy rating and a price target of $19.00.
For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.
Shares of Conatus Pharmaceuticals closed at $7.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Chardan Starts QumulusAI (QMLS) at Buy
- Piper Sandler Starts Jasper Therapeutics (JSPR) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
